

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

**VOLUNTARY ANNOUNCEMENT
OBTAINMENT OF PIC/S GMP CERTIFICATES
FOR TWO CONTRACT MANUFACTURING SITES
FOR EFSUBAGLUTIDE ALFA INJECTION**

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the **“Company”**) together with its subsidiaries, the **“Group”**) on a voluntary basis to inform the shareholders of the Company (the **“Shareholders”**) and potential investors of its recent business updates.

The board (the **“Board”**) of directors (the **“Directors”**) of the Company is pleased to announce that on 27 July 2026, two contract manufacturing sites of the Group, which are owned and operated by an independent third party, for injection project relating to Efsubaglutide Alfa located in the People's Republic of China (the **“PRC”**), had passed the Good Manufacturing Practice (**“GMP”**) compliance inspection conducted by the Brazilian Health Regulatory Agency (ANVISA) in accordance with the GMP standards of the Pharmaceutical Inspection Co-operation Scheme (**“PIC/S”**), and relevant GMP certificates had been granted by ANVISA.

PIC/S is an internationally recognised authority for pharmaceutical inspection and certification, comprising drug regulatory agencies from dozens of countries. It implements unified standards for GMP inspection and certification of medicinal products for human and veterinary use. GMP compliance inspection is one of the prerequisites for drug registration and approval. On a voluntary basis, PIC/S member countries and participating authorities mutually recognise GMP compliance inspection results.

The obtainment of the PIC/S GMP certificates signifies that the drug substance and drug product manufacturing and quality management systems of the Group's contract manufacturing sites comply with PIC/S GMP standards. This will further expand the Group's commercial production capacity for Efsubaglutide Alfa and facilitate its drug registration and commercialisation process in PIC/S member countries.

Cautionary Statement: The Company cannot guarantee that it will be able to ultimately develop market Efsubaglutide Alfa successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the People's Republic of China, 3 August 2026

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.